BACKGROUND:The quantitative insulin-sensitivity check index (QUICKI) has an excellent linear correlation with the glucose clamp index of insulin sensitivity (SIClamp). OBJECTIVE:It is important to investigate whether QUICKI would be useful index of insulin resistance (IR) to predict clinical outcome in ischemic stroke (IS) patients without type 2 diabetes mellitus (T2DM). METHODS AND MATERIAL:Prospective cohort patients who were diagnosed with IS and without a history of T2DM in the ACROSS-China registry were included from May 2008 to December 2009. And, QUICKI was calculated by the formula: 1/[log (fasting insulin, μU/mL) + log (fasting blood glucose, mg/dL)] and split into four quartiles. RESULTS:Of 1149 study participants, recurrent IS, all-cause death, and poor outcome occurred in 169 (14.71%), 72 (6.53%), and 261 (22.72%) cases, respectively in 1-year follow-up. Multivariable Cox proportional hazards analyses showed that the risk of incident primary endpoints was associated with a lower QUICKI quartile. In the Cox proportional hazard model, patients with the first QUICKI had an association with IS recurrence (adjusted hazard ratio, 2.90; 95% CI, 1.26-6.67; P = 0.001) and poor outcome (adjusted hazard ratio, 2.53; 95% CI, 1.06-5.99; P = 0.035), compared with those in the fourth quartile. Furthermore, the Kaplan-Meier survival analysis shown non-diabetic IS patients with a lower QUICKI had a higher mortality. CONCLUSIONS:QUICKI as an insulin sensitivity index might be a potential predictor of clinical outcomes for acute IS patients without T2DM.

Background Acute ischaemic stroke often leads to significant disability and mortality. Secondary brain injury caused by post-stroke immune and inflammatory responses worsens outcomes.Aim To assess the efficacy and safety of low-frequency deep transcranial magnetic stimulation (LF-dTMS), delivered with an H4 coil to target the insular and prefrontal cortex, and its potential effects on neuroimmune activity and recovery.Design This randomised, multicentre, open-label, parallel-group trial with blinded outcome assessment evaluates early LF-dTMS at 1 Hz using the H4 coil in adults with anterior-circulation acute ischaemic stroke treated within 48 hours of onset. Participants are randomly assigned in a 1:1 ratio to receive either standard care plus LF-dTMS or standard care alone. Active LF-dTMS is delivered as two sessions per day, 1200 pulses per session, for three consecutive days.Study outcomes The primary efficacy outcome is the growth in infarct volume from baseline to day 3, measured by diffusion-weighted MRI. The primary safety outcome is symptomatic intracranial haemorrhage within 3 days of treatment. Secondary outcomes include the modified Rankin Scale and serious adverse events at 90 days. Exploratory analyses in a predefined subgroup will involve dynamic plasma proteomics and single-cell RNA sequencing of peripheral mononuclear cells to understand immune responses (days 0, 3, 7), as well as resting-state functional MRI to evaluate the effects of neuromodulation on brain network connectivity.Summary This study will evaluate the feasibility, safety and preliminary efficacy of early LF-dTMS in acute stroke. It will provide proof-of-concept data on whether modulating post-stroke inflammation and neuroplasticity can improve outcomes. The findings will inform the design of a large definitive trial.Trial registration number NCT06064734.

BACKGROUND: The predictive value of acute-phase functional connectivity (FC) and neurovascular coupling (NVC) for functional prognosis in stroke patients remains unclear. METHODS: In a prospective cohort of 60 stroke patients, functional near-infrared spectroscopy assessed FC, brain activation pattern, and NVC (indexed by general linear model-derived beta values) within 7 days post-stroke. Functional outcome (modified Rankin Scale [mRS] score at 90 days) was dichotomized as favorable (mRS 0-1) or unfavorable. Least Absolute Shrinkage and Selection Operator regression selected variables for a Firth's logistic regression model predicting unfavorable outcome risk. RESULTS: Patients with a favorable outcome showed stronger global FC and bilateral cortical activation, whereas unfavorable patients exhibited predominantly contralesional compensatory pattern. Task-evoked responses were greater in favorable group in the ipsilesional primary motor cortex (iM1, t = 2.09, q = 0.04) and bilateral somatosensory association cortex (SAC, ipsilesional: t = 3.49, q < 0.001; contralesional: t = 2.34, q = 0.03). A Firth's logistic regression model incorporating four predictors-admission National Institutes of Health Stroke Scale score, the contralesional frontoparietal cortex-ipsilesional supramarginal gyrus FC value, iM1-beta value, and ipsilesional somatosensory association cortex-beta (iSAC-beta) value-achieved an area under the receiver-operating characteristic curve of 0.86, with the iSAC-beta value emerging as the leading neuroimaging contributor. CONCLUSION: Acute-phase FC strength and NVC are predictive of 90-day functional outcome after stroke. Ipsilesional SAC may represent a potential target for acute-phase prognostic stratification and mechanistically informed interventions.

Background In stroke recovery, the heterogeneity of lesions and symptoms makes it challenging to target neuromodulation precisely. Conventional one-size-fits-all neuromodulation approaches yield inconsistent outcomes, highlighting the need for precision strategies, such as lesion network mapping (LNM), to identify patient-specific symptom-related networks.Aim To evaluate the efficacy and safety of LNM-guided continuous theta-burst stimulation (cTBS) in improving motor recovery in patients with acute ischaemic stroke (AIS) treated within 14 days of symptom onset.Design The mapping navigated continuous theta-burst stimulation for motor recovery (MASTRE) trial is a multicentre, randomised, double-blind, sham-controlled Phase 2 study. Eligible participants will be randomly assigned (1:1) to receive either active LNM-guided cTBS or sham stimulation. For each participant, individualised stimulation targets will be determined through LNM, and real-time neuronavigation will be used to ensure precise modulation of the disrupted sensorimotor network. Treatment will consist of one daily session for seven consecutive days. In each session, cTBS will be delivered as bursts of three pulses at 50 Hz, repeated every 200 ms for 40 s.Study outcomes The primary efficacy outcome is the change in Fugl–Meyer Assessment total motor score from baseline to Day 7 post-randomisation. Safety assessments will include symptomatic intracranial haemorrhage and adverse events, which will be monitored through Day 90 post-randomisation.Discussion The MASTRE study introduces an innovative approach to optimise cTBS therapy in AIS patients by employing LNM to identify patient-specific targets within affected sensorimotor networks. Results from this trial may inform a new precision neurorehabilitation framework, promoting personalised therapeutic interventions tailored to individual neural connectivity profiles.Trial registration number NCT06400407.

Background The incidence of vascular cognitive impairment (VCI) is high in patients suffering from ischaemic stroke or transient ischaemic attack (TIA) or with vascular risk factors. Effective prevention strategies for VCI remain limited. Anaemia or low haemoglobin was found as an independent risk factor for adverse outcomes after acute stroke. Anaemia or low haemoglobin was possibly associated with an increased risk of poststroke cognitive impairment. Whether supplement of ferrous iron to correct anaemia reduces the risk of VCI and improves adverse outcomes in patients with ischaemic cerebrovascular disease remains uncertain.Aim We aim to introduce the design and rationale of the safety and efficacy of Ferrous iron on the prevention of Vascular cOgnitive impaiRment in patients with cerebral Infarction or TIA (FAVORITE) trial.Design FAVORITE is a randomised, placebo-controlled, double-blind, multicentre trial that compares supplement of ferrous iron with placebo for recent minor stroke/TIA patients complicated with mild anaemia or iron deficiency: Ferrous succinate sustained-release tablet 0.2 g (corresponding to 70 mg of elemental iron) once daily after or during breakfast for 12 weeks or placebo with much the same colour, smell and size as ferrous iron once daily during or after breakfast for 12 weeks. All paticipants will be followed within the next year.Study outcomes The primary effective outcome is the incidence of VCI at 3 months after randomisation and the primary safety outcome includes any gastrointestinal adverse event during 3 months.Discussion The FAVORITE trial will clarify whether supplement of ferrous iron to correct low haemoglobin reduces the risk of VCI in patients with recent ischaemic stroke or TIA complicated with mild anaemia or iron deficiency compared with placebo.Trial registration number NCT03891277

Numerous randomized controlled trials have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can reduce the risk of stroke across various populations, likely because of their effectiveness in lowering the incidence of ischemic stroke events. This review aimed to consolidate recent advancements in clinical research on the role of GLP-1RAs in preventing ischemic stroke and examine the mechanisms involved. GLP-1RAs have been shown to significantly improve several risk factors associated with ischemic stroke, such as elevated body mass index, hyperglycemia, and renal dysfunction, while potentially mitigating hypertension and dyslipidemia. Additionally, GLP-1RAs play a role in modulating the initiation of inflammation, endothelial dysfunction, and vascular inflammation in atherosclerosis, which may contribute to their protective effects against ischemic stroke. Nevertheless, further investigations are required to substantiate the efficacy of GLP-1RAs in ischemic stroke prevention and comprehensively elucidate the underlying mechanisms.

Objective:To investigate the correlation between fasting blood glucose (FPG) and neurological function in patients with acute ischemic stroke.Methods:A retrospective analysis was performed on 3 338 stroke patients admitted to Xuanwu Hospital of Capital Medical University within 24 hours of onset from November 2013 to October 2016. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. FPG, 2 hours postprandial-based blood glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), glycated hemoglobin A 1c (HbA 1c), serum creatinine (Scr), urea, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), homocysteine (Hcy), plasma fibrinogen (Fg) were detected. National institutes of health stroke scale (NIHSS), Glasgow coma index (GCS) and modified Rankin scale (MRS) were used to evaluate neurological function. Patients were divided into three groups according to different FPG levels on admission: normal blood glucose group (FPG<6.1 mmol/L, no history of diabetes, 1 507 cases), FPG impaired group (6.1 mmol/L≤FPG<7.0 mmol/L, 1 002 cases), diabetes group (FPG≥7.0 mmol/L or previous history of diabetes, 829 cases). According to NIHSS score, all patients were divided into neurological impairment group (NIHSS score>1 point, 1 906 cases) and normal neurological function group (NIHSS score≤1 point, 1 432 cases). The analysis of variance, t test, and χ2 test were used for comparison between groups. Pearson correlation analysis was used to analyze the correlation between FPG and neural function score. Multivariate logistic regression analysis was used to analyze the influencing factors of neurological function in acute ischemic stroke patients. Results:Compared with the normal blood glucose group and the impaired FPG group, SBP, DBP, FPG, ALT and AST were increased and the indexes of Scr, urea and TG were decreased in the diabetic group, the differences were statistically significant (all P<0.05). Compared with the normal blood glucose group, the SBP, DBP, FPG and ALT in the FPG impaired group were increased, while the AST, Scr, urea and TG were decreased, and the differences were statistically significant (all P<0.05). There were statistically significant differences in NIHSS, MRS and GCS scores among the three groups (all P<0.001). NIHSS and MRS scores in the diabetic group were significantly higher than those in the FPG impaired group, and GCS scores were significantly lower than those in the FPG impaired group (all P<0.001). NIHSS and MRS scores in the FPG impaired group were significantly higher than those in the normal blood glucose group, and GCS scores were significantly lower than those in the FPG impaired group (all P<0.05). FPG was positively correlated with NIHSS and MRS scores ( r=0.80, P<0.05; r=0.84, P<0.05), was negatively correlated with GCS scores ( r=-0.83, P<0.05). Multivariate logistic regression analysis showed that age, 2 hours postprandial-based blood glucose, hypoglycemic agents and FPG were all related to neurological function in stroke patients ( P<0.05). Conclusions:There is a significant correlation between FPG and neurological function score in patients with acute ischemic stroke. Patients with high FPG have more severe neurological function injury, poorer neurological function recovery state and worse consciousness state.

目的 探讨基于健康行动过程取向(health action process approach,HAPA)理论的罗盘式护理模式在中青年首发卒中患者中的应用效果. 方法 前瞻性、连续入组2021年6-12月首都医科大学附属北京天坛医院收治的18～45岁的首次卒 中患者,将患者随机分为对照组和干预组.对照组实施常规护理及延续性护理,干预组在对照组基础上实施基于HAPA理论的罗盘式护理模式3个月,比较两组患者干预后的卒中自我管理行为量表各维度得分及总分、卒中专用生活质量量表总分、焦虑自评量表总分、抑郁自评量表总分的改善情况. 结果 共计104例中青年首发卒中患者入组,脱落6例,最终干预组、对照组各纳入49例.干预组卒中自我管理行为量表总分、卒中专用生活质量量表总分均高于对照组(P<0.001,P=0.025);干预组焦虑自评量表总分、抑郁自评量表总分均低于对照组(P=0.001,P＜0.001). 结论 基于HAPA理论的罗盘式护理模式可有效提高患者自我管理能力,缓解患者的焦虑、抑郁情绪,提高其生活质量.

OBJECTIVE:This study aims to explore the relationship between baseline haemoglobin (Hb) content and poststroke cognitive impairment (PSCI) within 3 months following an acute ischaemic stroke or transient ischaemic attack (TIA). METHODS:Data are from a national multicentre prospective study that recruited patients with acute ischaemic stroke/TIA within 7 days. Cognitive function was assessed by the Montreal Cognitive Assessment (MoCA). PSCI was defined as a MoCA score ≤ 23 within 3 months after stroke onset. The relationship between Hb content and PSCI was assessed by a multiple regression model after adjusting for other potential confounders. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. RESULTS:A total of 2240 patients were included in this study. The average age was 60.96 ± 10.76 years old, and 784 (35.00%) patients experienced cognitive impairment within 3 months after acute ischaemic stroke/TIA. Patients with anaemia had a significantly lower MoCA score than those without anaemia at the 3-month follow-up (22.53 ± 5.56 versus 23.68 ± 4.77, P = 0.001). In a multiple regression analysis after adjusting for other confounders, patients with high Hb content were associated with a lower risk of PSCI than those with anaemia (OR 0.64, 95% CI 0.43-0.94, P = 0.02). Hb content was negatively related to the risk of PSCI within 3 months after stroke onset (OR 0.93, 95% CI 0.85-0.94 per 10 g/L increment, P = 0.04). CONCLUSION:Baseline Hb content was an independent protective predictor for PSCI in patients with acute ischaemic stroke/TIA.

朗格汉斯细胞组织细胞增生症是一种罕见的全身性疾病，约25%的患者累及鞍区，以多饮多尿起病常见。报道1例罕见的以闭经泌乳为主要临床表现的鞍区朗格汉斯细胞组织细胞增生症，详细阐述其诊疗流程，并讨论导致患者出现泌乳素增高的可能原因。

脑卒中是居世界首位的致残性疾病,并可导致一系列并发症的发生,包括认知功能障碍等.据统计,脑卒中后认知功能障碍的发病率为24％～53.4％ [1-2],是继阿尔茨海默病后第2位常见的痴呆病因.已有研究表明,急性脑卒中发生2周后, 52.38％的患者出现认知功能障碍,3个月后35.55％的患者出现认知功能障碍,且34.15％的患者在急性脑卒中发生后12个月仍遗留认知功能障碍 [3].高脂血症是动脉粥样硬化的主要危险因素,与痴呆和认知功能障碍的具体关联还未完全明确.临床研究发现,血脂代谢紊乱和脑卒中后认知功能障碍的发生具有一定的相关性 [4].然而,目前血脂水平和脑卒中后认知功能障碍的相关性研究并未得到临床的充分重视,其潜在的发病机制仍有待探索.因此,本文归纳总结相关研究结果,初步介绍了血脂水平与脑卒中后认知功能障碍的相关性.

Abstract Backgroud and purpose Triglyceride-glucose (TyG) index has been considered a surrogate marker of insulin resistance. We investigated the association between TyG index and stroke recurrence and compared the effectiveness of TyG index with homeostasis model assessment of insulin resistance (HOMA-IR) in predicting stroke recurrence and death in nondiabetic acute ischemic stroke patients. Methods Nondiabetic acute ischemic stroke patients from the ACROSS-China (Abnormal Glucose Regulation in Patients with Acute Stroke across China) registry were included. TyG index was performed and classified into four groups by quartiles. The outcomes were stroke recurrence and death within 1 year. The association between TyG index and the risk of stroke recurrence and death were analyzed by Cox regression models. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the prediction of TyG index and HOMA-IR for stroke recurrence and death. Delong test was used for comparing the differences between area under the curve (AUC) of TyG index and HOMA-IR. Results Among the 1226 patients included, the median (interquartile range) of TyG index was 5.8 (5.5–6.2). Both the third and fourth quartiles of TyG index were associated with an increased risk of stroke recurrence (adjusted hazard ratio 2.04, 95% confidence interval 1.26–3.31; adjusted hazard ratio 1.86, 95% confidence interval 1.13–3.06). Patients with fourth quartiles of TyG index were associated with a higher mortality risk (adjusted hazard ratio, 2.91; 95% confidence interval, 1.62–2.53). Regarding stroke recurrence within 1 year, the AUC (95% confidence interval) of the ROC curve for the TyG index was similar to that of the HOMA-IR[0.56 (0.52–0.61) vs 0.57 (0.52–0.61); P = 0.93]. Regarding death within 1 year, the AUCs (95% confidence interval) of the ROC curve for the TyG index and HOMA-IR were 0.55 (0.50–0.61) and 0.59 (0.53–0.64), respectively (P = 0.32). Conclusions Elevated TyG index was associated with an increased risk of stroke recurrence and death. However, neither of TyG nor HOMA-IR can be a qualified predictor of stroke recurrence and death in nondiabetic acute ischemic stroke patients.

Panvascular disease is not only a common comorbidity of type 2 diabetes mellitus (T2DM) but also the leading cause of disability and death in T2DM patients. To promote multidisciplinary cooperation and integration for early detection of panvascular disease in patients with T2DM, a group of Chinese researchers in the fields of cardiovascular disease, endocrinology, nephrology, neurology, and health management led by the Chinese Society of Cardiology and Chinese Medical Association, formed a “Chinese Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with Type 2 Diabetes” study group to review the latest evidence and major developments in relevant domestic and international disciplines to develop this consensus. The consensus covers the epidemiological characteristics, pathophysiological mechanisms, multidisciplinary collaborative treatments, and risk assessment and management of panvascular disease in patients with T2DM, with an emphasis on early-risk assessment of panvascular disease in patients with T2DM, including the assessment of risk factors, vascular structure and function, and target organ damage at least once a year. In addition, this consensus emphasized that managing panvascular disease in patients with T2DM requires the involvement of both patients and multidisciplinary physicians, and reinforces the importance of controlling blood glucose, blood pressure, and lipids and anti-platelet therapy in addition to lifestyle interventions. This consensus will help guide and assist clinicians regarding the standardized and comprehensive management of panvascular disease in patients with T2DM and improve patient prognosis.

目的 回顾性分析开始吸烟年龄与青年卒中之间的相关性.方法 选取2018年1月-2020年12月北京天坛医院收治的既往有吸烟或目前仍在吸烟的缺血性脑卒中患者.青年卒中定义为卒中发病年龄为18～45岁.利用多因素Logistic回归模型校正其他混杂因素后分析开始吸烟年龄与青年卒中之间的相关性.发生风险以比值比(OR)及95％的置信区间(CI)来表示.结果 本研究最后纳入869例缺血性卒中患者,平均开始吸烟年龄27.4±10.5岁,其中85(9.8％)例为青年卒中,817(94.5％)例为男性.青年卒中组平均开始吸烟年龄为21.6±5.9岁,显著低于中老年卒中组(28.0±10.7,P<0.001).多因素Logistic回归分析结果显示在调整其他混杂因素后,与≤25岁开始吸烟组相比,>25岁开始吸烟与较低的青年卒中发生风险相关(OR 0.17,95％CI 0.08～0.37,P<0.001).随着开始吸烟年龄的增长,青年卒中的发生风险随之降低(OR 0.41,95％CI 0.26～0.63每10岁递增,P<0.001).结论 开始吸烟年龄是青年卒中的独立预测因素,开始吸烟年龄越小,青年卒中发生风险越高.

老年患者因器官功能减退,储备能力下降,多种慢性病共存、衰弱、营养状态减弱等因素,手术风险增加.制定老年患者围术期风险防控策略,能够减少术后并发症的出现,保障手术安全.有效的多学科协作机制,可以整合医疗资源,进行整体诊疗;标准化流程设计,规范化治疗方案,是诊疗同质化的有利保障;加速康复外科策略的实施,能够对围术期进行优化管理;新技术、微创技术的应用,高水平老年围术期管理团队的发展,是老年手术安全性有效性的基石.只有加强老年围术期的管理,才能进一步有效降低手术风险,缩短住院时间,提升老年患者生活质量.

目的 探讨动脉粥样硬化性烟雾综合征的临床特征和手术疗效.方法 回顾性分析21例动脉粥样硬化性烟雾综合征病人的临床资料,对比手术前后mRS评分、卒中发生率及症状改善等情况,判断手术疗效.结果 所有病人术中荧光造影提示搭桥血管通畅性良好.术后搭桥血管闭塞1例,脑梗死3例,脑过度灌注1例,伤口浅表部位感染1例,均给予对症处理.影像学随访3～14个月,13例行MRA或CTA检查,搭桥血管通畅性良好6例,不通畅7例.10例行CT灌注(CT perfusion,CTP)或MRI动脉自旋标记灌注技术(arterial spin labeling,ASL)检查,大脑灌注改善7例,无明显改善3例.临床随访7～52个月,病人mRS评分降低13例,无变化6例,升高2例;随访期间未发生缺血性或出血性卒中等严重不良事件,无死亡病例.结论 有吸烟史、合并高血压且超重的中老年人群应警惕动脉粥样硬化性烟雾综合征的发生.颅内外搭桥手术可以显著改善病人预后,降低卒中发生率.

Objective: This study aims to discover whether insulin resistance is an independent predictor for antiplatelet drug resistance in patients with ischemic cerebrovascular disease. Methods: This study used a prospective cohort method. Patients diagnosed as minor ischemic stroke or transient ischemic attack (TIA) were enrolled successively. All patients have been administrated aspirin and/or clopidogrel and were tested for fasting glucose and insulin and platelet aggregation inhibition tests which was detected by light transmission aggregometry (LTA). The maximum platelet aggregation rate (AA) of >= 20% or the maximum platelet aggregation rate (ADP) of >= 50% was defined as antiplatelet drug resistance. Multivariable logistic regression was performed to estimate the association between HOMA-IR and antiplatelet drug resistance. Results: This study recruited successively 237 patients with mild-to-moderate ischemic stroke or TIA in Beijing Tiantan Hospital from 2018 to 2019. Of them 60 cases were recognized as having insulin resistance. There are 46 patients in insulin resistance group (76.7%) developed antiplatelet drug resistance, which was significantly more frequent than patients without insulin resistance (35%, P < 0.0001). Insulin resistance was an independent risk factor for antiplatelet drug resistance in patients with recent ischemic stroke/TIA after adjusted for confounding factors (Odds Ratio 5.281; 95%CI, 2.15 to 13.01, P < 0.0001). Conclusions: Insulin resistance was an independent predictor for development of antiplatelet drug resistance in patients with recent minor ischemic stroke or TIA. More attention should be paid to recognize these patients and antithrombotic effect should be monitored when antiplatelet drugs were applied to these patients.

目的 探究急性脑卒中患者入院时的血红蛋白(hemoglobin,Hb)含量与卒中后认知障碍(post-stroke cognitive impairment,PSCI)的相关性.方法 回顾性分析2018年10月至2020年10月首都医科大学附属北京天坛医院收治的197例急性脑卒中患者的临床资料,根据急性脑卒中患者3个月后是否出现PSCI分为认知功能障碍组(151例)和非认知功能障碍组(46例).记录两组患者的一般人口学特征,包括年龄、教育程度等;记录两组患者的实验室指标水平,包括Hb、同型半胱氨酸、高密度脂蛋白、低密度脂蛋白、尿酸、肌酐、糖化血红蛋白、空腹血糖、甘油三酯、胆固醇等;记录两组患者的高血压史、卒中家族史和神经系统损害程度等.分析急性脑卒中患者3个月后发生PSCI的独立性影响因素及入院时的Hb含量与急性脑卒中患者3个月后发生PSCI的相关性.结果 两组患者的高血压史、卒中家族史、入院时的美国国立卫生研究院卒中量表评分、入院时的改良Rankin量表评分、空腹血糖、糖化血红蛋白、同型半胱氨酸、高密度脂蛋白、低密度脂蛋白、甘油三酯、胆固醇和尿酸水平比较差异均无显著性(P>0.05);认知功能障碍组患者的年龄显著高于非认知功能障碍组(P<0.05),教育程度、Hb含量和肌酐水平均显著低于非认知功能障碍组(P<0.05).多因素logistic回归分析结果显示,在校正其他混杂因素后,入院时的Hb含量、年龄和教育程度是急性脑卒中患者3个月后发生PSCI的独立因素(P<0.05).Pearson相关性分析结果显示,入院时的Hb含量与急性脑卒中患者3个月后PSCI的发生呈正相关(r=0.267,P<0.001).结论 入院时的Hb含量是急性脑卒中患者3个月后发生PSCI的独立因素,且入院时的Hb含量越低,急性脑卒中患者3个月后发生PSCI的风险越高.